indican has been researched along with Acute Coronary Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldanzi, G; Chen, SC; Chiu, YW; Hsu, YL; Huang, JC; Hwang, SJ; Kuo, MC; Lee, SC; Liang, SS; Lin, YT; Wu, PH | 1 |
| Amano, H; Fujii, T; Ikeda, T; Koike, H; Morita, T; Nakanishi, R; Noike, R; Okubo, R; Saito, D; Tatebe, J; Toda, M; Watanabe, I; Yabe, T | 1 |
2 other study(ies) available for indican and Acute Coronary Syndrome
| Article | Year |
|---|---|
The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients.
Topics: Acute Coronary Syndrome; Cardiovascular System; Chemokines, CC; Cresols; Cysteine Endopeptidases; Female; Fibroblast Growth Factor-23; Heparan Sulfate Proteoglycans; Humans; Indican; Macrophage Inflammatory Proteins; Male; Middle Aged; Protein Binding; Renal Dialysis; Renal Insufficiency, Chronic; Signaling Lymphocytic Activation Molecule Family; Sulfuric Acid Esters; Toxins, Biological | 2021 |
Prognostic Utility of Indoxyl Sulfate for Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Female; Follow-Up Studies; Humans; Indican; Male; Middle Aged; Prognosis; Prospective Studies; Risk Assessment | 2019 |